Back to top
more

Ionis Pharmaceuticals (IONS)

(Real Time Quote from BATS)

$42.07 USD

42.07
286,126

-0.38 (-0.90%)

Updated Apr 25, 2024 11:34 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for IONS

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Ionis Pharmaceuticals, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 2,331 1,987 2,115 1,892 2,500
Receivables 98 26 62 76 63
Notes Receivable 0 0 0 0 0
Inventories 28 22 25 22 18
Other Current Assets 184 168 143 140 140
Total Current Assets 2,642 2,203 2,345 2,131 2,721
Net Property & Equipment 71 74 178 181 154
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 306
Intangibles 0 0 29 28 26
Deposits & Other Assets 105 75 60 50 28
Total Assets 2,990 2,534 2,612 2,390 3,233
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 26 18 12 17 16
Current Portion Long-Term Debt 44 0 4 300 2
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 216 189 127 156 104
Income Taxes Payable 2 6 0 1 33
Other Current Liabilities 160 98 98 108 118
Total Current Liabilities 448 312 241 583 273
Mortgages 0 9 60 60 60
Deferred Taxes/Income 241 288 352 424 490
Convertible Debt 1,188 1,167 1,161 456 710
Long-Term Debt 42 7 26 23 16
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 514 0 0 0 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 2,603 1,961 1,840 1,546 1,549
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 2,215 2,060 1,964 2,114 2,204
Retained Earnings -1,796 -1,430 -1,160 -1,249 -708
Other Equity -33 -57 -33 -21 188
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 387 573 772 843 1,685
Total Liabilities & Shareholder's Equity 2,990 2,534 2,612 2,390 3,233
Total Common Equity 387 573 772 843 1,685
Shares Outstanding 143.40 142.00 141.20 139.80 140.60
Book Value Per Share 2.70 4.03 5.47 6.03 11.98

Fiscal Year End for Ionis Pharmaceuticals, Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 2,331 2,236 2,385 2,347
Receivables NA 98 142 28 14
Notes Receivable NA 0 0 0 0
Inventories NA 28 26 26 22
Other Current Assets NA 184 181 178 160
Total Current Assets NA 2,642 2,585 2,617 2,543
Net Property & Equipment NA 71 71 92 85
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 0 0 0 0
Deposits & Other Assets NA 105 104 86 78
Total Assets NA 2,990 2,934 2,971 2,885
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 26 6 24 11
Current Portion Long-Term Debt NA 44 0 0 8
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 216 153 134 131
Income Taxes Payable NA 2 31 25 17
Other Current Liabilities NA 160 215 105 92
Total Current Liabilities NA 448 404 288 259
Mortgages NA 0 49 0 9
Deferred Taxes/Income NA 241 249 254 273
Convertible Debt NA 1,188 1,230 1,299 1,168
Long-Term Debt NA 42 0 16 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 513 510 513
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 2,603 2,619 2,543 2,399
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 2,215 2,148 2,118 2,089
Retained Earnings NA -1,796 -1,787 -1,639 -1,554
Other Equity NA -33 -46 -51 -49
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 387 315 428 487
Total Liabilities & Shareholder's Equity NA 2,990 2,934 2,971 2,885
Total Common Equity 0 387 315 428 487
Shares Outstanding 145.70 143.40 143.40 143.10 143.00
Book Value Per Share 0.00 2.70 2.20 2.99 3.40